Value-Based Care
Latest News
Reassessing Antidepressant Efficacy: A Meta-Analysis of Control Group Outcomes in SSRI, Psilocybin, and Esketamine Trials
July 31st 2025
A meta-analysis showed that control group outcomes in psilocybin trials for depression were significantly weaker than those in selective serotonin reuptake inhibitor (SSRI) and esketamine trials, suggesting that psilocybin’s large observed treatment effects may be inflated by methodological factors such as functional unblinding and expectancy bias.
